SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 12,220,000 shares, a growth of 39.5% from the May 15th total of 8,760,000 shares. Based on an average daily trading volume, of 1,910,000 shares, the days-to-cover ratio is presently 6.4 days. Approximately 17.6% of the shares of the stock are sold short.

SELLAS Life Sciences Group Trading Down 3.0%

SLS traded down $0.05 on Monday, hitting $1.61. 1,753,138 shares of the company were exchanged, compared to its average volume of 1,590,473. The company has a market cap of $160.64 million, a price-to-earnings ratio of -2.33 and a beta of 2.25. The firm has a 50-day moving average price of $1.53 and a two-hundred day moving average price of $1.27. SELLAS Life Sciences Group has a twelve month low of $0.77 and a twelve month high of $2.12.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. Equities analysts expect that SELLAS Life Sciences Group will post -0.57 EPS for the current year.

Insider Activity

In other news, Director Jane Wasman acquired 20,000 shares of SELLAS Life Sciences Group stock in a transaction that occurred on Friday, May 30th. The stock was purchased at an average cost of $1.69 per share, with a total value of $33,800.00. Following the purchase, the director now owns 30,400 shares in the company, valued at $51,376. This trade represents a 192.31% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several large investors have recently modified their holdings of the stock. Opus Capital Group LLC raised its holdings in SELLAS Life Sciences Group by 5.5% during the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company’s stock worth $248,000 after purchasing an additional 12,400 shares during the last quarter. Virtu Financial LLC grew its holdings in SELLAS Life Sciences Group by 30.9% during the 1st quarter. Virtu Financial LLC now owns 53,861 shares of the company’s stock valued at $58,000 after buying an additional 12,706 shares during the last quarter. Northern Trust Corp raised its holdings in shares of SELLAS Life Sciences Group by 33.6% in the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company’s stock worth $140,000 after acquiring an additional 33,878 shares during the last quarter. Geode Capital Management LLC increased its position in SELLAS Life Sciences Group by 21.2% during the 4th quarter. Geode Capital Management LLC now owns 733,546 shares of the company’s stock worth $763,000 after purchasing an additional 128,355 shares in the last quarter. Finally, Anson Funds Management LP raised its position in shares of SELLAS Life Sciences Group by 50.2% in the fourth quarter. Anson Funds Management LP now owns 1,192,266 shares of the company’s stock valued at $1,240,000 after buying an additional 398,431 shares during the last quarter. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.